07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Monoacylglycerol O-acyltransferase 2 (MOGAT2; MGAT2)

Endocrine/metabolic disease INDICATION: Endocrine/Metabolic; hypertriglyceridemia Mouse studies suggest inhibiting MOGAT2 could help treat hyperglyceridemia and other metabolic diseases. Optimization of an N-phenylindoline-5-sulfonamide-based MOGAT2 inhibitor (IC50 = 130 nM) resulted in a new lead compound that...
07:00 , Apr 2, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes; obesity Monoacylglycerol O-acyltransferase 2 (MOGAT2; MGAT2) A study in mice suggests that MGAT2 could be antagonized to treat type...